BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Diagnostics Accelerator and Target ALS Foundation Biomarker Discov
 ery RFP
DTSTART;VALUE=DATE:20220506
DTSTAMP:20260407T064015Z
UID:a9fd35838d5275b996b2d9cfaccd78ac9e3ce44b404c5ce5b130ebf0
CATEGORIES:Call for proposal
DESCRIPTION:Deadlines: \n\n	Letter of Intent: Wednesday\, March 2\, 2022\n
 	Full Proposals Solicited : Friday\, March 11\, 2022\n	Deadline for Submis
 sion of Full Proposals : Friday\, May 6\, 2022\n	Funding Decisions Announc
 ed : Friday\, May 27\, 2022\n\nAim:\n\nAdvancing biomarkers for neurodegen
 eration.\n\nAlzheimer’s disease\, frontotemporal dementia (FTD) and amyo
 trophic lateral sclerosis (ALS) are all heterogeneous at the clinical\, ne
 uropathological and genetic levels\, and increasing evidence indicates tha
 t the three disorders share common features. As such\, biomarker research 
 targeting mechanisms or pathways common across the three diseases holds pr
 omise to advance and facilitate biomarker discovery and validation.\n \nT
 wo Funding Mechanisms:\n\nOption 1: As a grant through Target ALS Foundati
 on.\n\nTwo broad categories:\n\n	Exploratory pilot studies that aim to tes
 t the utility of an existing fluid biomarker approach for the first time i
 n an Alzheimer's disease or related dementia and ALS population. These pro
 jects should already have preliminary human data from another neurodegener
 ative disease indication. Support will also be considered for transferring
  methods to measure biomarkers of interest currently in CSF to blood\, sal
 iva or urine.\n	Proof-of-principle analyses of biomarkers at a small scale
  (e.g.\, 50-100 human samples) that are supported by human data demonstrat
 ing that the candidate markers correspond with disease pathophysiology in 
 Alzheimer’s disease or FTD and ALS. For peripheral biomarkers\, prelimin
 ary assay performance data for the proposed studies should be included.\n	
  \n	Available funding $300\,000 USD per year\, maximum two-year period\n	
  \n\nOption 2: As a mission-related investment from the Diagnostics Accel
 erator at the ADDF\n\nProjects that succeed in the exploratory or proof-of
 -principle stage funded by Target ALS may be eligible for follow-on fundin
 g provided the biomarker is involved in Alzheimer’s disease or related d
 ementia disease pathophysiology. Direct applications are also welcome\, pr
 oviding the appropriate technical and business data packages can be assemb
 led. It is the aim of the Diagnostics Accelerator to advance biomarkers to
  the clinic.\n\n	Available funding: Collaborative projects\, as well as in
 dividual labs that are part of the collaborative projects funded through T
 arget ALS Foundation\, may be eligible for follow on funding through a one
 -time award of up to $500\,000 via a mission-related investment from the D
 iagnostics Accelerator\, provided the biomarker is involved in Alzheimer
 ’s disease or related dementia disease pathophysiology. Funding will be 
 provided to enable progress through the regulatory path with the aim of ma
 king the biomarker related tools and assays available to the worldwide com
 munity.\n\n\nHow to apply for either or both options:\n\nGo to the website
  for Diagnostics Accelerator and Target ALS Foundation Biomarker Discovery
  RFP\; use the “Log-in or Create Account” button at the bottom of the 
 page.\n\nFor further information:\n\nFor program-related inquiries:\n\n\n	
 Sarah Giardina\, PhD\, MBA\, Associate Director\, Biomarker Development\, 
 ADDF - sgiardina@alzdiscovery.org\n	Manish Raisinghani\, M.B.B.S\, PhD\, C
 EO\, Target ALS - manish.raisinghani@targetals.org\n\n\nFor application su
 bmission inquiries:\n\n\n	Mission Related Investments Team - grants@alzdis
 covery.org\n\nContact the Research Office for information or if you decide
  to submit a proposal.\n 
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR